NCT05067634
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
레지스트리 요약
- 진행 상태
- 완료 (COMPLETED)
- 질환/조건
- Partial Epilepsy
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 3
- 목적
- 치료
- 중재 유형
- 약물
- 개입·치료
- Xcopri
- Lead Sponsor
- SK Life Science, Inc. (산업계)
캐시 시각: 2026-10-23 21:36:54
요약
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
카카오 로그인 후 의뢰